NEW YORK, NY / ACCESSWIRE / January 31, 2020 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Adamas Pharmaceuticals, Inc. (NASDAQGM:ADMS)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/adamas-pharmaceuticals-inc-loss-submission-form?prid=5393&wire=1
Lead Plaintiff Deadline: February 10, 2020
Class Period: August 8, 2017 to September 30, 2019
Allegations against ADMS include that: (1) health insurers were excluding Adamas's primary product, GOCOVRI, from their prescription formularies or requiring patients to use "step therapy" - i.e., making patients try immediate-release amantadine prior to covering GOCOVRI; (2) the rapid increase in physicians prescribing GOCOVRI during the Class Period was not due to its efficacy; and (3) as a result of the foregoing, the Company's financial statements about Adamas's business, operations, and prospects were materially false and misleading at all relevant times.
Merit Medical Systems, Inc. (NASDAQ:MMSI)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/merit-medical-systems-inc-loss-submission-form?prid=5393&wire=1
Lead Plaintiff Deadline: February 3, 2020
Class Period: February 26, 2019 to October 30, 2019
Allegations against MMSI include that: (a) the integrations of acquired companies Cianna Medical, Inc. and Vascular Insights, LLC, including their products, sales people, and R&D facilities, had caused operational disruptions and reduced sales and were months behind schedule; (b) sales of acquired company products had slowed substantially due to pre-acquisition pipeline fill, in particular for Vascular Insights products which, as late as July 2019, had zero orders during FY19; and (c) in light of the foregoing, the Company's reported financial guidance for FY19 and FY20 was made without a reasonable basis.
Opera Limited (NASDAQ:OPRA)
If you suffered a loss, contact us at: http://www.wongesq.com/pslra-1/opera-limited-loss-submission-form?prid=5393&wire=1
Lead Plaintiff Deadline: March 24, 2020
Class Period: (a) Opera American depositary shares pursuant and/or traceable to the Company's initial public offering commenced on or about July 27, 2018 and/or (b) Opera securities between July 27, 2018 and January 15, 2020,
Allegations against OPRA include that: (i) Opera's sustainable growth and market opportunity for its browser applications was significantly overstated; (ii) Defendants' funded, owned, or otherwise controlled loan services applications and/or businesses relied on predatory lending practices; (iii) all the foregoing, once revealed, were reasonably likely to have a material negative impact on Opera's financial prospects, especially with respect to its lending applications' continued availability on the Google Play Store; and (iv) as a result, the Offering Documents and Defendants' statements were materially false and/or misleading and failed to state information required to be stated therein.
To learn more contact Vincent Wong, Esq. either via email [email protected] or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]
SOURCE: The Law Offices of Vincent Wong